Journal article
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
Abstract
BACKGROUND: There is a direct relationship between bodyweight and risk of diabetes. Lorcaserin, a selective serotonin 2C receptor agonist that suppresses appetite, has been shown to facilitate sustained weight loss in obese or overweight patients. We aimed to evaluate the long-term effects of lorcaserin on diabetes prevention and remission.
METHODS: In this randomised, double-blind, placebo-controlled trial done in eight countries, we recruited …
Authors
Bohula EA; Scirica BM; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Kanevsky E; Murphy SA; Leiter LA; Dwyer JP
Journal
The Lancet, Vol. 392, No. 10161, pp. 2269–2279
Publisher
Elsevier
Publication Date
11 2018
DOI
10.1016/s0140-6736(18)32328-6
ISSN
0140-6736